Comparative analysis of ABO-incompatible kidney transplantation with ABO-compatible transplantation : a single-center experience from eastern India

Abstract EN

This study aimed to compare the outcomes of ABO-incompatible kidney transplantation (ABOiKT) with ABO-compatible kidney transplantation (ABOcKT) in a single- center study.

A total of 30 consecutive ABOiKT recipients (ABOiKTR) from April 2014 to June 2015 were included in this study.

All the patients received rituximab 200 mg/body for B-cell depletion.

Plasmapheresis was done for anti-ABO antibody removal.

The target anti-ABO titer was kept at <1:8.

The outcomes of this group of patients were compared with that of thirty ABOcKT recipients.

Both the groups received similar induction therapy with antithymocyte globulin and methylprednisolone.

After a follow-up period of one year, the outcomes of both the groups were compared in terms of patient survival, graft survival, graft function, incidence of rejections, infective complications, and duration of posttransplant hospital stay.

The patient survival in both the groups of patients was 96.67%.

The death-censored graft survival was 96.67% in both the groups.

The average serum creatinine level, estimated glomerular filtration rate, incidence of rejections, infective episodes, and posttransplant hospital stay were comparable in both the groups.

The outcomes of ABOiKT were comparable with ABOcKT and as such, this modality can expand the living donor pool substantially